|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001891 |
Purpose
Coronary artery disease (CAD) can cause poor blood flow and supply to the heart muscle. It can result in irreversible damage to the heart muscle and poor function. Before treating patients with heart disease it is important to know how well the heart is functioning. Echocardiography is a diagnostic test that can measure heart function. If part of the heart muscle is not working properly due to previous damage, echocardiography can provide information about how much improvement can be expected after treatment (surgery or angioplasty).
The purpose of this study is to compare the accuracy of myocardial contrast echocardiography (MCE) to dobutamine echocardiography to detect the potential for damaged heart muscle to be treated and function in patients with heart disease.
Myocardial contrast echocardiography (MCE) does not use radioactivity. It uses sound waves like standard echocardiography. However, with MCE patients receive an injection of a "contrast agent" directly into the blood stream through a vein. The contrast agent, called Optison, is made of tiny microbubbles smaller than red blood cells. The echocardiogram can detect these microbubbles in the small blood vessels of the heart muscle and allow researchers to find areas of the heart receiving less blood flow than others.
Echocardiography with Dobutamine does not use radioactivity. It uses sound waves, like standard echocardiography. During this echocardiogram patients receive doses of a medication called dobutamine that stimulates the heart to beat stronger and faster. Heart muscle that does not beat stronger after dobutamine is probably dead, usually as a result of a previous heart attack.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Disease Heart Diseases |
Procedure: Myocardial contrast echocardiography Procedure: Dobutamine echocardiography |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Efficacy Study |
| Official Title: | Assessment of Myocardial Viability Utilizing Myocardial Contrast Echocardiography |
| Estimated Enrollment: | 200 |
| Study Start Date: | May 1999 |
| Estimated Study Completion Date: | March 2001 |
Dobutamine echocardiography has become a valuable technique for the evaluation of myocardial viability in patients with coronary artery disease (CAD) and dysfunctional myocardium because it can accurately predict which myocardial segments will show contractile recovery after successful revascularization. Myocardial contrast echocardiography (MCE) offers the potential to evaluate tissue perfusion at the level where oxygen transfer to the myocytes occurs. MCE, therefore, can provide information regarding the functional status of the myocardial microvasculature which has a close relationship with myocellular integrity. The purpose of this study is to evaluate the accuracy of MCE compared to dobutamine echocardiography to detect myocardial viability in patients with CAD and resting wall motion abnormalities.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients undergoing evaluation for CAD who show at least two myocardial segments with wall motion abnormalities on a baseline echocardiogram will be offered to participate in this study.
Patients will be adults older than 21 years of age.
No pre-menopausal patients who are lactating, are pregnant or potentially pregnant as judged by history, physical examination, ultrasound or urine pregnancy test.
No one with unstable angina.
No subjects with recent myocardial infarction (less than 1 month).
No one with frequent ectopy which precludes adequate imaging acquisition.
No subjects with significant hypertension (systolic blood pressure greater than 170 mm Hg).
No hypotension with basal sitting systolic arterial pressure less than 100 mm HG confirmed 30 minutes later.
No subjects with sinus tachycardia greater than or equal to 100 beats/minute.
No atrial fibrillation.
No inadequate two-dimensional echocardiographic windows.
Contacts and Locations More Information
| Study ID Numbers: | 990108, 99-H-0108 |
| Study First Received: | November 3, 1999 |
| Last Updated: | March 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001891 |
| Health Authority: | United States: Federal Government |
|
CABG Hibernation LV Function |
Microbubbles Revascularization Coronary Artery Disease |
|
Arterial Occlusive Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases |
Arteriosclerosis Ischemia Dobutamine Coronary Artery Disease |
|
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic beta-Agonists Adrenergic Agents Cardiotonic Agents Sympathomimetics Physiological Effects of Drugs Cardiovascular Agents |
Protective Agents Pharmacologic Actions Adrenergic Agonists Autonomic Agents Therapeutic Uses Cardiovascular Diseases Peripheral Nervous System Agents |
